RheinCell Therapeutics to be acquired by Catalent, Accelerating the Industrialization of iPSC-based Therapies
Catalent Pharma Solutions, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics, cell and gene therapy and consumer health products, has agreed to acquire RHEINCELL Therapeutics. This strategic decision will allow RHEINCELL to continue its growth plans and support the cell and gene therapy industry with leading technology and services.
Catalent shares our patient-first philosophy and commitment to providing development partners with the most flexible and high-quality services that allow for accelerated timelines to the clinic and ultimately commercial supply. With the combination of RHEINCELL’s expertise in iPSC GMP banks and Catalent’s cell therapy custom development and manufacturing offering, our customers will have increased access to technology, development and services across the entire iPSC value chain.
Furthermore, Catalent’s global capabilities and extensive experience in GMP manufacturing, fill/finish, analytics, and clinical supply services will facilitate RHEINCELL in the advancement of quality systems, processes, and infrastructure. Catalent’s Cell and Gene Therapy Gosselies campus is conveniently located 2.5 hours away from RHEINCELL’s headquarters and production site.
Read the press release here.
A note to our valued customers can be found here.